Skye Bioscience Statistics

Total Valuation

Skye Bioscience has a market cap or net worth of $55.44 million. The enterprise value is -$12.52 million.

Market Cap	55.44M
Enterprise Value	-12.52M

Important Dates

The next estimated earnings date is Friday, May 9, 2025, after market close.

Earnings Date	May 9, 2025
Ex-Dividend Date	n/a

Share Statistics

Skye Bioscience has 30.97 million shares outstanding. The number of shares has increased by 420.79% in one year.

Current Share Class	30.97M
Shares Outstanding	30.97M
Shares Change (YoY)	+420.79%
Shares Change (QoQ)	+2.96%
Owned by Insiders (%)	2.99%
Owned by Institutions (%)	46.60%
Float	17.26M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.81
P/TBV Ratio	0.81
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 16.32, with a Debt / Equity ratio of 0.01.

Current Ratio	16.32
Quick Ratio	15.77
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-40.30

Financial Efficiency

Return on equity (ROE) is -80.48% and return on invested capital (ROIC) is -53.09%.

Return on Equity (ROE)	-80.48%
Return on Assets (ROA)	-44.56%
Return on Invested Capital (ROIC)	-53.09%
Return on Capital Employed (ROCE)	-44.13%
Revenue Per Employee	n/a
Profits Per Employee	-$1.66M
Employee Count	16
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Skye Bioscience has paid $10,071 in taxes.

Income Tax	10,071
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -87.24% in the last 52 weeks. The beta is 1.89, so Skye Bioscience's price volatility has been higher than the market average.

Beta (5Y)	1.89
52-Week Price Change	-87.24%
50-Day Moving Average	2.20
200-Day Moving Average	3.90
Relative Strength Index (RSI)	50.88
Average Volume (20 Days)	1,694,535

Short Selling Information

The latest short interest is 2.28 million, so 7.36% of the outstanding shares have been sold short.

Short Interest	2.28M
Short Previous Month	2.06M
Short % of Shares Out	7.36%
Short % of Float	13.22%
Short Ratio (days to cover)	10.99

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-30.19M
Pretax Income	-42.28M
Net Income	-26.57M
EBITDA	-29.90M
EBIT	-30.19M
Earnings Per Share (EPS)	-$0.73

Full Income Statement

Balance Sheet

The company has $68.42 million in cash and $455,590 in debt, giving a net cash position of $67.96 million or $2.19 per share.

Cash & Cash Equivalents	68.42M
Total Debt	455,590
Net Cash	67.96M
Net Cash Per Share	$2.19
Equity (Book Value)	68.15M
Book Value Per Share	2.20
Working Capital	66.49M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$25.24 million and capital expenditures -$1.60 million, giving a free cash flow of -$26.84 million.

Operating Cash Flow	-25.24M
Capital Expenditures	-1.60M
Free Cash Flow	-26.84M
FCF Per Share	-$0.87

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Skye Bioscience does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-420.79%
Shareholder Yield	-420.79%
Earnings Yield	-47.92%
FCF Yield	-48.41%

Analyst Forecast

The average price target for Skye Bioscience is $16.60, which is 827.37% higher than the current price. The consensus rating is "Buy".

Price Target	$16.60
Price Target Difference	827.37%
Analyst Consensus	Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	29.71%

Stock Forecasts

Stock Splits

The last stock split was on September 8, 2023. It was a reverse split with a ratio of 0.004:1.

Last Split Date	Sep 8, 2023
Split Type	Reverse
Split Ratio	0.004:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	2